Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial....
Original Article: Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 percent: study